STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #1397 by analyst upside · 2026-09-16
MANE
Veradermics, Incorporated
Healthcare · Market Cap $4B · P/E 0x
ANALYST PRICE TARGET
+57.4%
implied upside to consensus target
Current Price $103.89
Consensus Target $163.5
Bull Target $182.0
Bear Target $135.0
Analysts Covering 6
ANALYST CONSENSUS - BUY
Strong Buy
1
Buy
5
Hold
0
Sell
0
52-Week Low $32.0
52-Week High $131.24
YTD Return +175.2%
FUNDAMENTALS
Market Cap $4B
P/E Ratio (TTM) N/A
Forward P/E N/A
EPS (TTM) $-2.49
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) N/A
Profit Margin N/A
52-WEEK RANGE
52-Week Low $32.0
52-Week High $131.24
Current Price $103.89
Bear Target $135.0
Bull Target $182.0
● Now $103.89 ● Target $163.5
TRADING DATA
Avg Volume 745K
YTD Return +175.2%
Analyst Count 6
Consensus Buy
Upside to Target +57.4%
Last Updated 2026-09-16

ANALYST SUMMARY

Veradermics, Incorporated (MANE) is currently trading at $103.89 with a Wall Street consensus price target of $163.5, implying potential upside of 57.4% over the next 12 months. 6 analysts currently cover MANE, with a consensus rating of Buy - 100% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $182.0, while the most cautious has a target of $135.0.

MANE operates in the Healthcare sector with a market capitalisation of $4B. The stock is up 175.2% year-to-date and is currently trading near the upper end of its 52-week range of $32.0 – $131.24.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for MANE, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Citigroup - Reiterated
Buy → Buy 2026-07-16 Building track record
Needham - Reiterated
Buy → Buy 2026-07-15 20% win rate (5 calls)
B. Riley Securities ● Initiated
Buy 2026-07-15 17% win rate (6 calls)
Jefferies - Reiterated
Buy → Buy 2026-07-07 50% win rate (6 calls)
LifeSci Capital ● Initiated
Outperform 2026-06-16 Building track record
Needham ● Initiated
Buy 2026-06-02 20% win rate (5 calls)
Citigroup - Reiterated
Buy → Buy 2026-05-18 Building track record
Leerink Partners - Reiterated
Outperform → Outperform 2026-04-22 29% win rate (7 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
63
out of 100
Coverage depth
15/30
Consensus clarity
21/30
Vote unanimity
25/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →